表紙:免疫療法薬:世界の市場
市場調査レポート
商品コード
996380

免疫療法薬:世界の市場

Immunotherapy Drugs: Global Markets

出版日: | 発行: BCC Research | ページ情報: 英文 143 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.86円
免疫療法薬:世界の市場
出版日: 2021年03月18日
発行: BCC Research
ページ情報: 英文 143 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界における免疫治療薬の市場規模は、2020年の1,398億米ドルから2025年までに2,044億米ドルに成長し、2020年から2025年の年平均成長率(CAGR)は7.9%が見込まれています。

免疫療法薬用モノクローナル抗体製品の市場規模は、2020年の1,132億米ドルから2025年までに1,533億米ドルに成長し、2020年から2025年のCAGRは6.3%が見込まれています。

免疫療法薬のチェックポイント阻害剤製品の市場規模は、2020年の263億米ドルから、2025年までに509億米ドルに成長し、2020年から2025年のCAGRは14.1%が見込まれています。

当レポートでは、世界の免疫治療薬市場について包括的に調査し、2019年から2020年までのデータ、2022年の推定値、および2025年までの複合年間成長率(CAGR)の予測を使用した、世界の市場の動向の分析、現在の市場規模と予測の評価、新製品のパイプライン分析、規制シナリオ、および市場の成長に影響を与える推進要因、課題、機会の詳細な分析、免疫療法、併用免疫療法の説明、および細胞性適応免疫をどのように標的とするかについての議論、業界の主要なプレーヤーの市場シェア分析、および彼らの技術的な長所と短所、および革新的なマーケティング慣行に関する議論などについて提供しています。

目次

第1章 イントロダクション

  • 調査目標・目的
  • レポートの範囲
  • 調査手法
  • 市場規模の推計
  • 情報源
  • 1次調査
  • 2次調査
  • 地理的内訳
  • アナリストの経歴
  • BCCカスタム調査
  • BCC Research の関連レポート

第2章 サマリーとハイライト

第3章 市場と技術の背景

  • 免疫療法
  • 併用免疫療法に向けて
  • 細胞性適応免疫に焦点を当てる
  • ファインチューニング vs. がん免疫の強化
  • 初期 vs. 進行期のがん免疫療法
  • 個別化医療のパラダイム
  • 臨床的に重要ながんの種類
  • 肺がん
  • 乳がん
  • 結腸直腸がん
  • 胃がん
  • 白血病
  • がんにおける免疫療法の未来
  • 感染症
  • 自己免疫疾患に対する免疫療法
  • 感染症に対する免疫療法
  • 自己免疫疾患治療としての生物学的製剤
  • 自己免疫疾患治療の動向
  • 免疫療法の種類
  • チェックポイント阻害剤
  • 医療のアンメットニーズ
  • 患者を層別化するための新しいバイオマーカー
  • 再発/難治性の患者
  • 治療の有効性と忍容性
  • 革新的な戦略
  • 新規のターゲットアプローチ
  • モノクローナル抗体
  • インターロイキン
  • インターフェロン

第4章 市場力学

  • 免疫療法市場の強み
  • 高齢化人口の増加
  • 病気の発生率の上昇
  • 特許の有効期限
  • 成長するパイプライン
  • コスト削減への取り組み
  • 政府のインセンティブ
  • コラボレーションとパートナーシップ
  • 合併と買収
  • 免疫療法市場の弱点
  • 製造プロセス
  • プロセスの定義とテストおよび検証
  • 熟練人材の不足
  • 規制ガイドライン
  • 特許訴訟
  • 免疫療法市場への脅威
  • 予測不可能な規制状況
  • 開業医/薬局別処方箋
  • 競合
  • 免疫療法市場における機会
  • 新興市場
  • 技術革新と改善されたプロセス知識
  • 価格設定

第5章 製薬業界に対するCOVID-19の影響

  • 短期的な影響
  • 需要の変化
  • コミュニケーションとプロモーションのリモートインタラクションへのシフト
  • 研究開発の変更
  • 長期的な影響
  • COVIDに関連しない医薬品の承認の遅れ
  • 製薬業界の自給自足
  • 健康関連商品の消費動向の変化

第6章 製品タイプ別の市場内訳

  • 概要
  • モノクローナル抗体
  • 市場概要
  • 市場収益
  • 市場シェア
  • 地域別の市場
  • 市場概要
  • 市場収益
  • 市場シェア
  • チェックポイント阻害剤
  • ペンブロリズマブ
  • コンパニオン診断
  • 臨床試験プログラム
  • ペンブロリズマブの予測
  • ニボルマブ(オプジーボ)
  • コンパニオン診断
  • 臨床試験プログラム
  • ニボルマブの予測
  • アテゾリズマブ(Tecentriq)
  • コンパニオン診断
  • 臨床試験プログラム
  • アテゾリズマブの予測
  • アベルマブ(バベンシオ)
  • コンパニオン診断
  • 臨床試験プログラム
  • アベルマブの天気予報
  • デュルバルマブ(インフィンジ)
  • コンパニオン診断
  • 臨床試験プログラム
  • デュルバルマブの予測
  • ヤーボイ(イピリムマブ)
  • 地域別の市場
  • 市場収益
  • 市場シェア
  • インターフェロンとインターロイキン
  • 市場収益
  • 地域別の市場
  • 疾患領域別市場

第7章 地域別の市場内訳

  • 市場概要と考察
  • 北米
  • 米国
  • カナダ
  • 欧州
  • アジア太平洋
  • 中国
  • 日本
  • その他の地域

第8章 企業プロファイル

  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BAYER AG
  • BRISTOL MYERS SQUIBB
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON
  • VIATRIS INC. (FORMERLY MYLAN)
  • NOVARTIS AG
  • PFIZER INC.
  • VERTEX PHARMACEUTICALS INC.
図表

List of Tables

  • Summary Table B : Global Market for Immunotherapy Drugs, by Region, Through 2025
  • Summary Table A : Global Market for Immunotherapy Drugs, by Product Type, Through 2025
  • Table 1 : Stages of Lung Cancer
  • Table 2 : Biologics as Autoimmune Disorder Therapies
  • Table 3 : Adverse Events Associated with Immune-Checkpoint Blockade
  • Table 4 : Evolution of Monoclonal Antibodies
  • Table 5 : Advantages and Disadvantages of Monoclonal Antibodies
  • Table 6 : Murine Monoclonal Antibodies
  • Table 7 : Chimeric Monoclonal Antibodies
  • Table 8 : Humanized Monoclonal Antibodies
  • Table 9 : Human Monoclonal Antibodies
  • Table 10 : Selected Approved Interferon Alpha Analogs
  • Table 11 : Global Market for Immunotherapy Drugs, by Product Type, Through 2025
  • Table 12 : Global Market for Monoclonal Antibodies, by Type, Through 2025
  • Table 13 : Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
  • Table 14 : Global Market for Monoclonal Antibody Drugs, by Region, Through 2025
  • Table 15 : Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
  • Table 16 : Global Market for Checkpoint Inhibitors, 2019-2025
  • Table 17 : Pembrolizumab Approved Indications
  • Table 18 : Nivolumab Approved Indications
  • Table 19 : Atezolizumab Approved Indications
  • Table 20 : Avelumab Approved Indications
  • Table 21 : Durvalumab Approved Indications
  • Table 22 : Global Market of Checkpoint Inhibitors, by Region, Through 2025
  • Table 23 : Global Market Shares for Checkpoint Inhibitors, by Region, 2019
  • Table 24 : Global Market for Interferons and Interleukins, Through 2025
  • Table 25 : Global Market for Interferons and Interleukins, by Region, Through 2025
  • Table 26 : Global Market for Immunotherapy, by Therapeutic Area, Through 2025
  • Table 27 : Global Market for Immunotherapy Drugs, by Region, Through 2025
  • Table 28 : North American Market for Immunotherapy Drugs, by Country, Through 2025
  • Table 29 : North American Market for Immunotherapy Drugs, by Product Type, Through 2025
  • Table 30 : European Market for Immunotherapy Drugs, by Country, Through 2025
  • Table 31 : European Market for Immunotherapy Drugs, by Product Type, Through 2025
  • Table 32 : Asia-Pacific Market for Immunotherapy Drugs, by Country, Through 2025
  • Table 33 : Asia-Pacific Market for Immunotherapy Drugs, by Product Type, Through 2025
  • Table 34 : Chinese Market Statistics
  • Table 35 : Japanese Market Statistics
  • Table 36 : AbbVie: Product Portfolio
  • Table 37 : Amgen: Product Portfolio
  • Table 38 : AstraZeneca: Product Portfolio
  • Table 39 : Bayer AG: Product Portfolio
  • Table 40 : Johnson & Johnson: Product Portfolio
  • Table 41 : Viatris: Product Portfolio
  • Table 42 : Novartis AG: Product Portfolio
  • Table 43 : Pfizer: Product Portfolio
  • Table 44 : Pfizer: Pipeline Product Portfolio

List of Figures

  • Summary Figure A : Global Market for Immunotherapy Drugs, by Product Type, 2019-2025
  • Summary Figure B : Global Market for Immunotherapy Drugs, by Region, 2019-2025
  • Figure 1 : Annual Incidence and Mortality Data for Lung Cancer in the U.S., 1990-2020
  • Figure 2 : Annual Incidence and Mortality Data for Lung Cancer in Five EU Countries, 1975-2020
  • Figure 3 : Annual Incidence and Mortality Data for Lung Cancer in the Rest of the World, 1975-2020
  • Figure 4 : Five-Year Survival Rates, by Lung Cancer Stage
  • Figure 5 : Annual Incidence and Mortality Data for Breast Cancer in the U.S., 1975-2020
  • Figure 6 : Annual Incidence and Mortality Data for Breast Cancer in Five E.U. Countries., 1975-2020
  • Figure 7 : Annual Incidence and Mortality Data for Breast Cancer in Japan, 1975-2020
  • Figure 8 : Annual Incidence and Mortality Data for Breast Cancer in the Rest of the World, 1975-2020
  • Figure 9 : Five-Year Survival Rates, by Breast Cancer Stage
  • Figure 10 : Annual Incidence and Mortality Data for Colorectal Cancer in the U.S., 1975-2020
  • Figure 11 : Annual Incidence and Mortality Data for Colorectal Cancer in Five EU Countries, 1975-2020
  • Figure 12 : Annual Incidence and Mortality Data for Colorectal Cancer in Japan, 1975-2020
  • Figure 13 : Annual Incidence and Mortality Data for Colorectal Cancer in the Rest of the World, 1975-2020
  • Figure 14 : Five-Year Survival Rates, by Colorectal Cancer Stage
  • Figure 15 : Annual Incidence and Mortality Data for Stomach Cancer in the U.S., 1975-2020
  • Figure 16 : Annual Incidence and Mortality Data for Stomach Cancer in Five EU Countries, 1975-2012
  • Figure 17 : Annual Incidence and Mortality Data for Stomach Cancer in Japan, 1975-2020
  • Figure 18 : Annual Incidence and Mortality Data for Stomach Cancer in the Rest of the World, 1975-2020
  • Figure 19 : Five-Year Survival Rates, by Stomach Cancer Stage
  • Figure 20 : Annual Incidence and Mortality Data for Leukemia in the U.S., 1975-2020
  • Figure 21 : Annual Incidence and Mortality Data for Leukemia in Five EU Countries, 1975-2020
  • Figure 22 : Annual Incidence and Mortality Data for Leukemia in Japan, 1975-2020
  • Figure 23 : Annual Incidence and Mortality Data for Leukemia in the Rest of the World, 1975-2020
  • Figure 24 : Potential Targets for Checkpoint Inhibition in Clinical Evaluation
  • Figure 25 : SWOT Analysis of Immunotherapy Market
  • Figure 26 : Impact of COVID-19 on the Pharmaceutical Industry
  • Figure 27 : Global Market for Immunotherapy Drugs, 2019-2025
  • Figure 28 : Global Market Shares for Immunotherapy Drugs, by Product Type, 2019
  • Figure 29 : Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
  • Figure 30 : Global Market for Monoclonal Antibody Drugs, by Region, 2019-2025
  • Figure 31 : Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
  • Figure 32 : Pembrolizumab Comprehensive Clinical Trial Programs, by Status
  • Figure 33 : Pembrolizumab Comprehensive Clinical Trial Programs, by Therapy
  • Figure 34 : Pembrolizumab Comprehensive Clinical Trial Programs, by Cancer Type
  • Figure 35 : Global Market for Pembrolizumab, 2019-2025
  • Figure 36 : Nivolumab Comprehensive Clinical Trial Programs, by Status
  • Figure 37 : Nivolumab Comprehensive Clinical Trial Programs, by Therapy
  • Figure 38 : Nivolumab Comprehensive Clinical Trial Programs, by Cancer Type
  • Figure 39 : Global Market for Nivolumab, 2019-2025
  • Figure 40 : Atezolizumab Comprehensive Clinical Trial Programs, by Status
  • Figure 41 : Atezolizumab Comprehensive Clinical Trial Programs, by Therapy
  • Figure 42 : Atezolizumab Comprehensive Clinical Trial Programs, by Cancer Type
  • Figure 43 : Global Market for Atezolizumab, 2019-2025
  • Figure 44 : Avelumab Comprehensive Clinical Trial Programs, by Status
  • Figure 45 : Avelumab Comprehensive Clinical Trial Programs, by Therapy
  • Figure 46 : Avelumab Comprehensive Clinical Trial Programs, by Cancer Type
  • Figure 47 : Global Market for Avelumab, 2019-2025
  • Figure 48 : Durvalumab Comprehensive Clinical Trial Programs, by Status
  • Figure 49 : Durvalumab Comprehensive Clinical Trial Programs, by Therapy
  • Figure 50 : Durvalumab Comprehensive Clinical Trial Programs, by Cancer Type
  • Figure 51 : Global Market for Durvalumab, 2019-2025
  • Figure 52 : Global Market for Ipilimumab, 2019-2025
  • Figure 53 : Global Market for Checkpoint Inhibitors, by Region, 2019-2025
  • Figure 54 : Global Market Shares for Checkpoint Inhibitors, by Region, 2019
  • Figure 55 : Global Market for Interferons and Interleukins, by Region, 2019-2025
  • Figure 56 : Global Market Shares for Immunotherapy Drugs, by Region, 2019
  • Figure 57 : North American Market Shares for Immunotherapy Drugs, by Product Type, 2019
  • Figure 58 : European Market for Immunotherapy Drugs, by Country, 2019-2025
  • Figure 59 : European Market for Immunotherapy Drugs, by Product Type, 2019-2025
  • Figure 60 : Asia-Pacific Market Shares for Immunotherapy Drugs, by Product Type, 2019
  • Figure 61 : AbbVie Inc.: Annual Revenue, 2016-2019
  • Figure 62 : AbbVie: Revenue Share, by Region/Country, 2019
  • Figure 63 : AbbVie: Revenue Share, by Business Unit, 2019
  • Figure 64 : Amgen: Annual Revenue, 2016-2019
  • Figure 65 : Amgen: Revenue Share, by Region/Country, 2019
  • Figure 66 : Amgen: Revenue Share, by Products, 2019
  • Figure 67 : AstraZeneca: Annual Revenue, 2016-2019
  • Figure 68 : AstraZeneca: Revenue Share, by Region/Country, 2019
  • Figure 69 : AstraZeneca: Revenue Share, by Business Unit, 2019
  • Figure 70 : Bayer AG: Annual Revenue, 2016-2019
  • Figure 71 : Bayer AG: Revenue Share, by Region, 2019
  • Figure 72 : Bayer AG: Revenue Share, by Business Unit, 2019
  • Figure 73 : Bristol Myers Squibb: Annual Revenue, 2016-2019
  • Figure 74 : Bristol Myers Squibb: Revenue Share, by Region/Country, 2019
  • Figure 75 : Bristol Myers Squibb: Revenue Share, by Brands, 2019
  • Figure 76 : Hoffmann-La Roche: Annual Revenue, 2016-2019
  • Figure 77 : Hoffmann-La Roche: Revenue Share in Pharmaceutical Segment, by Region/Country, 2019
  • Figure 78 : Hoffmann-La Roche: Revenue Share, by Business Segment, 2019
  • Figure 79 : Johnson & Johnson: Annual Revenue, 2016-2019
  • Figure 80 : Johnson & Johnson: Revenue Share, by Region/Country, 2019
  • Figure 81 : Johnson & Johnson: Revenue Share, by Business Unit, 2019
  • Figure 82 : Viatris: Annual Revenue, 2016-2019
  • Figure 83 : Viatris: Revenue Share, by Region, 2019
  • Figure 84 : Viatris: Revenue Share, by Business Unit, 2019
  • Figure 85 : Novartis AG: Annual Revenue, 2015-2019
  • Figure 86 : Novartis AG: Revenue Share, by Region/Country, 2019
  • Figure 87 : Novartis AG: Revenue Share, by Business Segment, 2019
  • Figure 88 : Pfizer: Annual Revenue, 2016-2019
  • Figure 89 : Pfizer: Revenue Share, by Region/Country, 2019
  • Figure 90 : Pfizer: Revenue Share, by Business Segment, 2019
  • Figure 91 : Vertex Pharmaceuticals: Annual Revenue, 2016-2019
  • Figure 92 : Vertex Pharmaceuticals: R&D Expense Annual Revenue, 2017-2019
  • Figure 93 : Vertex Pharmaceuticals: Revenue Share, by Business Segment, 2019
目次
Product Code: PHM249A

Highlights:

The global market for immunotherapy drugs should grow from $139.8 billion in 2020 to $204.4 billion by 2025, at compound annual growth rate (CAGR) of 7.9% for the period of 2020-2025.

The monoclonal antibodies product for immunotherapy drugs should grow from $113.2 billion in 2020 to $153.3 billion by 2025, at a CAGR of 6.3% for the period of 2020-2025.

The checkpoint inhibitors product for immunotherapy drugs should grow from $26.3 billion in 2020 to $50.9 billion by 2025, at a CAGR of 14.1% for the period of 2020-2025.

Report Scope:

The global immunotherapy market can be segmented into the following types: checkpoint inhibitors, monoclonal antibodies, interferons and interleukins. This report does not include other immunotherapies such as vaccines and hormones.

The scope of the report includes an overview of the global market and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.

The report discusses technological, regulatory and economic trends that are affecting the market. It also explains the major drivers and regional dynamics of the global market and current trends within the industry.

Regional analysis includes North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy and Rest of Europe), Asia-Pacific (China, India, Japan and Rest of Asia-Pacific) and rest of the world (RoW).

Report Includes:

  • 20 data tables and 26 additional tables
  • An overview of the global market for immunotherapy drugs
  • Estimation of the market size and analyses of global market trends, with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) though 2025
  • Evaluation of current market size and forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth
  • Description of immunotherapy, combination immunotherapy and discussion on how it targets on cell-mediated adaptive immunity
  • Market share analysis of the immunotherapy drugs based on type of drug, therapy area, end user and region
  • Information on personalized treatment paradigm, details of clinically significant types of cancers and discussion on future of immunotherapy in cancer
  • Details of checkpoint inhibitors, monoclonal antibodies, interleukins and interferons; and coverage of innovative strategies and novel targeted approaches for immunotherapy
  • Discussion on fine tuning versus boosting cancer immunity and early versus advanced stage cancer immunotherapy
  • Market share analysis of the major players in the industry, and discussion on their technological strengths and weakness, and innovative marketing practices
  • Comprehensive company profiles of major players of the industry, including Amgen Inc., Bayer AG, Johnson & Johnson, Novartis AG and Pfizer Inc.

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Scope of Report
  • Methodology
  • Market Estimates
  • Information Sources
  • Primary Research
  • Secondary Research
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Immunotherapy
  • Towards Combination Immunotherapy
  • Focusing on Cell-mediated Adaptive Immunity
  • Fine Tuning Vs. Boosting Cancer Immunity
  • Early Vs. Advanced Stage Cancer Immunotherapy
  • Personalized Treatment Paradigm
  • Clinically Significant Types of Cancers
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Stomach Cancer
  • Leukemia
  • Future of Immunotherapy in Cancer
  • Infectious Diseases
  • Immunotherapy against Autoimmune Disorders
  • Immunotherapies against Infectious Diseases
  • Biologics as Autoimmune Disorder Therapies
  • Trends in Autoimmune Disorder Therapies
  • Types of Immunotherapies
  • Checkpoint Inhibitors
  • Unmet Medical Needs
  • New Biomarkers to Stratify Patients
  • Relapse/Refractory Patients
  • Treatment Efficacy and Tolerability
  • Innovative Strategies
  • Novel Targeted Approaches
  • Monoclonal Antibodies
  • Interleukins
  • Interferons

Chapter 4 Market Dynamics

  • Strengths of Immunotherapy Market
  • Growing Aging Population
  • Rising Incidence of Diseases
  • Patent Expirations
  • Growing Pipeline
  • Drive to Reduce Costs
  • Government Incentives
  • Collaborations and Partnerships
  • Mergers and Acquisitions
  • Weaknesses of the Immunotherapy Market
  • Manufacturing Process
  • Process Definition and Testing and Validation
  • Lack of Skilled Personnel
  • Regulatory Guidelines
  • Patent Litigation
  • Threats to Immunotherapy Market
  • Unpredictable Regulatory Landscape
  • Prescriptions by Medical Practitioners/Pharmacies
  • Competition
  • Opportunities in the Immunotherapy Market
  • Emerging Markets
  • Technological Innovation and Improved Process Knowledge
  • Pricing

Chapter 5 Impact of COVID-19 on the Pharmaceutical Industry

  • Short-term Impact
  • Change in Demand
  • Shift of Communication and Promotions to Remote Interactions
  • Changes to R&D
  • Long-term Impact
  • Delayed Approvals for Non-COVID-related Pharmaceutical Products
  • Self-sufficiency in the Pharmaceutical Industry
  • Changes in Consumption Trends in Health-related Products

Chapter 6 Market Breakdown by Product Type

  • Overview
  • Monoclonal Antibodies
  • Market Overview
  • Market Revenue
  • Market Share
  • Market by Region
  • Market Overview
  • Market Revenue
  • Market Share
  • Checkpoint Inhibitors
  • Pembrolizumab
  • Companion Diagnostic
  • Clinical Trial Program
  • Forecast for Pembrolizumab
  • Nivolumab (Opdivo)
  • Companion Diagnostic
  • Clinical Trial Program
  • Forecast for Nivolumab
  • Atezolizumab (Tecentriq)
  • Companion Diagnostic
  • Clinical Trial Program
  • Forecast for Atezolizumab
  • Avelumab (Bavencio)
  • Companion Diagnostic
  • Clinical Trial Program
  • Forecast for Avelumab
  • Durvalumab (Imfinzi)
  • Companion Diagnostic
  • Clinical Trial Program
  • Durvalumab Forecasts
  • Yervoy (Ipilimumab)
  • Market by Region
  • Market Revenue
  • Market Share
  • Interferons and Interleukins
  • Market Revenue
  • Market by Region
  • Market by Disease Area

Chapter 7 Market Breakdown by Region

  • Market Overview and Discussion
  • North America
  • United States
  • Canada
  • Europe
  • Asia-Pacific
  • China
  • Japan
  • Rest of the World

Chapter 8 Company Profiles

  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BAYER AG
  • BRISTOL MYERS SQUIBB
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON
  • VIATRIS INC. (FORMERLY MYLAN)
  • NOVARTIS AG
  • PFIZER INC.
  • VERTEX PHARMACEUTICALS INC.